Consultations
We consult on proposed changes to the way we regulate medicines, medical devices and biologicals. Additional consultations about changes to the Poisons Standard can be found in the Scheduling decisions (interim) section of our publications hub.
Filter results
You can narrow down the results using the filters
Topic
- Scheduling (national classification system) (68)
- Medical devices (62)
- Therapeutic goods regulation (13)
- Over the counter medicine (12)
- Prescription medicines (10)
- Complementary medicines (8)
- Medicines (8)
- Advisory bodies and committees (7)
- Legislation (6)
- Manufacturing (5)
- Biologicals (4)
- Labelling and packaging (4)
- Advertising (3)
- Listed medicines (3)
- Non-prescription medicines (3)
- Fees and payments (2)
- Sunscreens (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Clinical trials (1)
- Import and export (1)
- In Vitro Diagnostic medical devices (IVDs) (1)
- Medical devices safety (1)
- Medicinal cannabis hub (1)
- Medicines safety (1)
- Nicotine vaping products hub (1)
- Other therapeutic goods (1)
- Safety (1)
- Unique Device Identification (UDI) Hub (1)
More on consultations
Find more scheduling consultations on the Poisons Standard in our Interim decisions.
Read the details of recent consultations, submissions and decisions at the TGA Consultation hub.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Search
212 result(s) found, displaying 51 to 75
- Closed onConsultationConsultation: Proposed refinements to the regulation of medical devices that are substances introduced into the human body via a body orifice or applied to the skinSubmissions published and summarised as part of a consultation on medical devices that are substances for introduction into the body.
- Closed onConsultationConsultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): TriptansOutcomes of the consultation and submissions received have now been published
- Closed onConsultationConsultation: Remaking of standards and legislative instruments for human cell and tissue (HCT) products, blood and blood componentsThe TGA is seeking feedback on a proposal to remake some of the legislative instruments relating to human cell and tissue (HCT) products (including blood and blood components), which sunset in October 2021. Closing date: 11 July 2021
- Closed onConsultationConsultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)Outcomes of the consultation and submissions received have now been published
- Closed onConsultationConsultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): MentholOutcomes of the consultation and submissions received have now been published
- Closed onConsultationConsultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylateThe TGA is seeking feedback on proposed advisory statements for OTC medicines containing methyl salicylate for inclusion in RASML. Closing date: 18 May 2021
- Closed onConsultationConsultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistaminesOutcomes of the consultation and submissions received have now been published
- Closed onConsultationConsultation: Proposed improvements to the Therapeutic Goods Advertising CodeThe outcomes of the public consultation into proposed improvements to the Therapeutic Goods Advertising Code have been published.
- Closed onConsultationConsultation: Proposed refinements to the regulation of personalised medical devicesThe closing date has been extended and now closes on 14 July
- Closed onConsultationConsultation: Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirementA further update by the TGA on the proposed reforms to medicinal cannabis, labelling and packaging requirements.
- Closed onConsultationImpact of amendments to the application process for inclusion of Class I medical devices in the Australian Register of Therapeutic Goods (ARTG)The Australian Government is undertaking a significant program to reform the regulation of therapeutic goods in Australia. As part of the Australian Government Department of Health, the Therapeutic Goods Administration (TGA) regulates therapeutic goods, and is responsible for implementing the Government’s reforms. The TGA has issued this survey as part of the Government’s reform program.
- Closed onConsultationConsultation: Australian Medical Device Regulations definition of Central Circulatory System (CCS)A submission summary on the Australian Regulations definition of CCS consultation is available on our consultation hub
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard - Joint ACMS/ACCS #28, June 2021Proposed amendments to the Poisons Standard, including substances in hand sanitisers. Closing date: 27 May 2021
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard - ACCS #31, June 2021Proposed amendments to the Poisons Standard. Closing date: 4 June 2021
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard (sodium nitrite) - Joint ACMS/ACCS #28, June 2021The closing date for this consultation has been extended until 27 May 2021
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard - ACMS #34, June 2021Proposed amendments to the Poisons Standard. Closing date: 27 May 2021
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard (oral contraceptives) - ACMS #34, June 2021Proposed amendments to the Poisons Standard. Closing date: 27 May 2021
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard - Joint ACMS-ACCS, June 2021This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 23 June 2021 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard (sodium nitrite) - Joint ACMS-ACCS, June 2021This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 23 June 2021 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
- Closed onConsultationIMDRF consultation: Assessment and Decision Process for the Recognition of a Conformity Assessment Body Conducting Medical Device Regulatory ReviewsThe IMDRF working group is seeking comments from interested parties on the proposed guidance document. Closing date: 19 April 2021
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard - ACMS, June 2021This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 23-24 June 2021 meeting of the Advisory Committee on Medicines Scheduling (ACMS).
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard (oral contraceptives) - ACMS, June 2021This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 23-24 June 2021 meeting of the Advisory Committee on Medicines Scheduling (ACMS).
- Closed onConsultationConsultation: Repurposing of prescription medicinesThe closing date has been extended until 30 March 2021.
- Closed onConsultationConsultation: Proposed regulatory options for medical devices containing nanomaterialsTGA is seeking comments on whether the Australian medical device regulatory framework should be aligned to the EU framework for medical devices containing nanomaterials. Closing date: 9 April 2021
- Closed onConsultationConsultation: Proposal for clarifying regulatory requirements for residual claims for disinfectantsThis consultation is to obtain feedback in relation to proposals to provide clarity on residual claims for disinfectants. Closing date: 26 March 2021